Omega Pharma NV:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Omega Pharma NV - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3337
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Omega Pharma NV (Omega Pharma), a subsidiary of Perrigo Company plc, is a pharmaceutical company focusing on the development, manufacture and sale of prescription-free or Over the Counter (OTC) health and personal care products. The company’s product portfolio includes cough and cold products, skin care products, pain relief products, vitamins, minerals, and nutritional supplements. Its products cater to gastro-intestinal disorders, respiratory issues, eye care, weight management, food supplements, baby care, and skin care. Besides, the company offers auto-diagnostic products such as body temperature meters, ovulation meters and blood pressure meters. It distributes these products to customers through retail distribution and drug store chains. Omega Pharma is headquartered in Nazareth, Belgium.

Omega Pharma NV – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Omega Pharma NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Omega Pharma NV, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Omega Pharma Acquires Arterin Business Of Pharco For US$13 Million 11
Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 12
Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 13
Partnerships 15
Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 15
NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 16
Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 17
Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 18
Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 19
Licensing Agreements 20
Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 20
BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 21
Equity Offering 22
Omega Pharma Completes Public Offering Of Shares For US$237 Million 22
Debt Offering 23
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$383 Million 23
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$237.6 Million 24
Omega Pharma Completes Public Offering Of Bonds Due 2019 For US$158.4 Million 25
Acquisition 26
Perrigo Acquires Omega Pharma for USD4.76 Billion 26
Omega Pharma Acquires Naturoteek 28
Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For US$1.26 Billion 29
Omega Pharma NV – Key Competitors 31
Omega Pharma NV – Key Employees 32
Omega Pharma NV – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Joint Venture 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
Omega Pharma NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Omega Pharma NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Omega Pharma NV, Deals By Therapy Area, 2012 to YTD 2018 8
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Omega Pharma Acquires Arterin Business Of Pharco For US$13 Million 11
Omega Pharma Acquires Rights To Optalidon From Novartis Consumer Health 12
Omega Pharma Completes Acquisition Of Identified Non-Core OTC Brands In Europe From GSK For US$614 Million 13
Dompe Farmaceutici Enters into Distribution Agreement with Omega Pharma 15
NovaMedica Enters into Co-Marketing Agreement with Omega Pharma 16
Omega Pharma Enters Into Co-Marketing Agreement With Kwizda Pharma For BronchoStop Cough Products 17
Omega Pharma Enters Into Joint Venture With Cavi Brands To Form OmegaLabs 18
Omega Pharma Enters Into Co-Development Agreement With Sienna Biotec 19
Hikma Pharma Enters into Licensing Agreement with Omega Pharma Trading 20
BioLineRx Enters into Licensing Agreement with Omega Pharma for BL-5010 21
Omega Pharma Completes Public Offering Of Shares For US$237 Million 22
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$383 Million 23
Omega Pharma Completes Public Offering Of Bonds Due 2017 For US$237.6 Million 24
Omega Pharma Completes Public Offering Of Bonds Due 2019 For US$158.4 Million 25
Perrigo Acquires Omega Pharma for USD4.76 Billion 26
Omega Pharma Acquires Naturoteek 28
Couckinvest Completes Acquisition Of Remaining Stake In Omega Pharma For US$1.26 Billion 29
Omega Pharma NV, Key Competitors 31
Omega Pharma NV, Key Employees 32
Omega Pharma NV, Subsidiaries 33
Omega Pharma NV, Joint Venture 34

List of Figures
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Omega Pharma NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Omega Pharma NV:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • AdAlta Ltd (1AD):製薬・医療:M&Aディール及び事業提携情報
    Summary AdAlta Ltd (AdAlta), formerly AdAlta Pty Ltd, is a biotechnology company that discovers and develops new class of protein therapeutics for wide range of human diseases. The company's lead i-body candidate, AD-114, is being developed for the treatment of idiopathic pulmonary fibrosis and othe …
  • Autolus Therapeutics Plc (AUTL):製薬・医療:M&Aディール及び事業提携情報
    Summary Autolus Therapeutics Plc (Autolus), formerly Autolus Therapeutics Limited is a clinical-stage biopharmaceutical company which offers programmed T cell immunotherapies for the treatment of hematological cancers and solid tumors. The company utilizes its T-cell programming and manufacturing te …
  • Alteogen Inc (196170):製薬・医療:M&Aディール及び事業提携情報
    Summary Alteogen Inc (Alteogen) is a biotech company that develops proprietary antibody-drug conjugate and antibody biosimilars. The company’s pipeline products include ALT-P1, ALT-Q2, ALT-P7, ALT-Q5, ALT-L9 and ALT-L2. Its products are used for long-acting human growth hormone, long-acting factor V …
  • Southern Minnesota Municipal Power Agency:企業の戦略的SWOT分析
    Southern Minnesota Municipal Power Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and …
  • The Centre of Excellence for Prevention of Organ Failure:医療機器:M&Aディール及び事業提携情報
    Summary The Centre of Excellence for Prevention of Organ Failure (PROOF Centre) is a healthcare center that provides blood-based biomarker tests. The center conducts biomarker programs to develop simple blood tests for transplant patients and patients with chronic organ disease and biomarkers in tra …
  • Anavex Life Sciences Corp (AVXL)-製薬・医療分野:企業M&A・提携分析
    Summary Anavex Life Sciences Corp (Anavex) is a clinical-stage biopharmaceutical company that focuses on developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases, other central nervous system (CNS) diseases, pain and various types of cancer. The c …
  • eTheRNA Immunotherapies NV:製薬・医療:M&Aディール及び事業提携情報
    Summary ETheRNA Immunotherapies NV (eTheRNA) is a developer of novel immunotherapies for the treatment of cancers and infectious diseases. The company’s pipeline products include mRNA-based immunotherapies for various indications such as melanoma, triple negative breast cancer and infectious disease …
  • Salzgitter AG:企業の戦略・SWOT・財務情報
    Salzgitter AG - Strategy, SWOT and Corporate Finance Report Summary Salzgitter AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Lipocine Inc (LPCN):企業の財務・戦略的SWOT分析
    Summary Lipocine Inc (Lipocine) is a pharmaceutical company that develops and commercializes treatment for men's and women's health. The company’s pipeline products for men’s health include LPCN 1111 and LPCN 1021; and for women’s health include LPCN 1107. Its LPCN 1111 is an oral testosterone produ …
  • British American Tobacco Plc (BATS):企業の財務・戦略的SWOT分析
    British American Tobacco Plc (BATS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Kyushu Financial Group Inc (7180):企業の財務・戦略的SWOT分析
    Kyushu Financial Group Inc (7180) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and we …
  • Samsung Heavy Industries Co., Ltd.
    Samsung Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Samsung Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Shionogi & Co., Ltd.:企業の戦略・SWOT・財務情報
    Shionogi & Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Shionogi & Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Beazer Homes USA Inc:企業の戦略・SWOT・財務情報
    Beazer Homes USA Inc - Strategy, SWOT and Corporate Finance Report Summary Beazer Homes USA Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • EFU General Insurance Company Limited:企業の戦略・SWOT・財務情報
    EFU General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report Summary EFU General Insurance Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analy …
  • KFG Resources Ltd (KFG):企業の財務・戦略的SWOT分析
    Summary KFG Resources Ltd (KFG) is a petroleum and natural gas exploration company that supplies natural gas. The company produces crude oil and natural gas through its reserves. Its oil and gas reserves are located in Mississippi, Wilcox, and Louisiana. KFG’s Mississippi’s projects comprise Carthag …
  • Daikin Industries, Ltd.:企業の戦略・SWOT・財務分析
    Daikin Industries, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Daikin Industries, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Chokwang Paint Co Ltd (004910):企業の財務・戦略的SWOT分析
    Chokwang Paint Co Ltd (004910) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • Oxford Immunotec Ltd:医療機器:M&Aディール及び事業提携情報
    Summary Oxford Immunotec Ltd (Oxford Immunotec) a subsidiary of Oxford Immunotec Global Plc is a medical device company that offers proprietary tests for immune-regulated conditions. The company offers in vitro diagnostic, T-SPOT CMV Test, C6 Lyme ELISA Test, T-Cell Xtend Reagent. It offers T-SPOT.T …
  • NBN Co Ltd:企業の戦略的SWOT分析
    NBN Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆